Rein Therapeutics Inc.
IPO Year: 2017
Exchange: NASDAQ
Recent Analyst Ratings for Rein Therapeutics Inc.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/28/2025 | $8.00 | Buy | Rodman & Renshaw |
Rein Therapeutics Inc. Press Releases
Fastest customizable press release news feed in the world
Rein Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Rein advanced the clinical development of its lead asset, LTI-03, and aims to initiate a Phase 2 trial for the treatment of idiopathic pulmonary fibrosis (IPF) in the first half of 2025 Positive topline results from Cohort 2 (5 mg BID) of the Phase 1b clinical trial of LTI-03 in IPF patients demonstrated dose dependent effects in five biomarkers evaluated, with four biomarkers achieving statistical significance in the combined Cohort 1 and Cohort 2 data set AUSTIN, Texas, April 7, 2025 /PRNewswire/ -- Rein Therapeutics, Inc. (NASDAQ:RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fib
Rein Therapeutics Inc. Analyst Ratings
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Rodman & Renshaw initiated coverage on Rein Therapeutics with a new price target
Rodman & Renshaw initiated coverage of Rein Therapeutics with a rating of Buy and set a new price target of $8.00
Rein Therapeutics Inc. SEC Filings
SEC Form 10-K filed by Rein Therapeutics Inc.
10-K - Rein Therapeutics, Inc. (0001420565) (Filer)
SEC Form NT 10-K filed by Rein Therapeutics Inc.
NT 10-K - Rein Therapeutics, Inc. (0001420565) (Filer)